A new study reveals how a critical imbalance in bile acids—the substances made by the liver that help digest fats—can trigger liver diseases, including hepatocellular carcinoma (HCC), the most common ...

Chromatin architecture is frequently altered in cancers, including one of the most prevalent cancers, hepatocellular carcinoma (HCC). Emerging evidence suggests that liquid-liquid phase separation ...

We aim to develop non-viral nanocarriers to deliver ribonucleoproteins (RNP) targeting Glypican-3 (GPC3) and investigate the biological and immunological therapeutic effects from CRISPR-Cas9 GPC3 gene ...

The precise use of immunotherapy agents in locally advanced head and neck squamous cell carcinoma has not been clearly delineated ... Those patients with high-risk pathology, defined as positive ...

The FDA has granted full approval to Bristol Myers Squibb’s (BMS) dual immunotherapy regimen of Opdivo (nivolumab) plus Yervoy (ipilimumab) for adults with unresectable or metastatic hepatocellular ...

as a first-line treatment for adults with unresectable or metastatic hepatocellular carcinoma (HCC). Median overall survival, the primary outcome measure, was 23.7 months in those randomized to ...

The FDA approved nivolumab and ipilimumab for unresectable or metastatic hepatocellular carcinoma, a prevalent and deadly liver cancer in the U.S. CHECKMATE-9DW trial results showed improved ...